Deciphering tumor-intrinsic and immune characteristics in resectable non-small cell lung cancer treated with neoadjuvant pembrolizumab and chemotherapy
Our study identified molecular biomarkers for pathological and survival outcomes, which may inform optimal treatment decision-making, guide postoperative therapy, and improve survival outcomes for stage II-III patients with resectable NSCLC.
Authors
- Xiaoxuan Sun
- Jian You (ORCID: https://orcid.org/0000-0002-9637-8379)
- Song Wang (ORCID: https://orcid.org/0000-0002-9302-8410)
- Yulong Chen (ORCID: https://orcid.org/0000-0003-4754-3056)
- Qiuxiang Ou (ORCID: https://orcid.org/0000-0002-2961-2057)
- Hua Bao (ORCID: https://orcid.org/0000-0001-5774-8755)
- Gang Zhao (ORCID: https://orcid.org/0000-0002-3904-0216)
- Ran Zhang (ORCID: https://orcid.org/0000-0002-4142-805X)
- Jiangyan Zhang (ORCID: https://orcid.org/0000-0001-8057-6373)
- Yanjun Su (ORCID: https://orcid.org/0009-0002-0725-1243)
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-10-14
- DOI
- https://doi.org/10.1186/s12967-025-06965-7
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00